An activated sludge modeling framework for xenobiotic trace chemicals (ASM-X): Assessment of diclofenac and carbamazepine

Biotechnology and Bioengineering

Volumn 109, Issue 11, 2012, Pages 2757-2769

  Plósz, Benedek Gy ^a,b   Langford, Katherine H ^a   Thomas, Kevin V ^a  

^a NORWEGIAN INSTITUTE FOR WATER RESEARCH   (Norway)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Biological wastewater treatment; Cometabolic biotransformation; Non steroidal anti inflammatory drug; Psycho active drug; Sorption and sequestration; Trace chemicals or micro pollutants

Indexed keywords

BIOLOGICAL WASTE WATER TREATMENT; COMETABOLIC BIOTRANSFORMATION; MICROPOLLUTANTS; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; PSYCHO-ACTIVE DRUG;

AMIDES; BIOCHEMISTRY; BIOCONVERSION; ESTIMATION; EXPERIMENTS; FORECASTING; LOADING; ORGANIC CHEMICALS; SORPTION;

COMPUTER SIMULATION;

CARBAMAZEPINE; DICLOFENAC;

ACTIVATED SLUDGE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; PHYSICAL PARAMETERS; PREDICTIVE VALUE; SIMULATION; SOLIDS RETENTION TIME; WASTE COMPONENT REMOVAL; WASTE WATER MANAGEMENT;

BIOTRANSFORMATION; CARBAMAZEPINE; DICLOFENAC; MODELS, BIOLOGICAL; SEWAGE; WATER POLLUTANTS, CHEMICAL; WATER PURIFICATION; XENOBIOTICS;

EID: 84866760758     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24553     Document Type: Article

References (44)

1. American Public Health Association. 1995. Standard methods for the examination of water and wastewater. APHA: Washington DC.
2. Bendz D, Paxeus NA, Ginn TR, Loge FJ. 2005. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Hoje River in Sweden. J Hazard Mater 122(3):195-204.
3. Clara M, Strenn B, Gans O, Martinez E, Kreuzinger N, Kroiss H. 2005. Removal of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional wastewater treatment plants. Water Res 39(19):4797-4807.
4. Chang HL, Alvarez-Cohen L. 1995. Model for the cometabolic biodegradation of chlorinated organics. Environ Sci Technol 29(9):2357-2367.
5. Criddle CS. 1993. The kinetics of cometabolism. Biotechnol Bioeng 41:1048-1056.
6. Dec J, Bollag JM. 1997. Determination of covalent and noncovalent binding interactions between xenobiotic chemicals and soil. Soil Sci 162(12):858-874.
7. Delgadillo-Mirquez L, Lardon L, Steyer JP, Patureau D. 2011. A new dynamic model for bioavailability and cometabolism of micropollutants during anaerobic digestion. Water Res 45(15):4511-4521.
8. Franco A, Trapp S. 2008. Estimation of the soil-water partition coefficient normalized to organic carbon for ionisable organic chemicals. Env Toxicol Chem 27(10):1995-2004.
9. Gerrity D, Trenholm RA, Snyder SA. 2011. Temporal variability of pharmaceuticals and illicit drugs in wastewater and the effects of a major sporting event. Water Res 45(17):5399-5411.
10. Grady CPL, Jr., Daigger GT, Lim HC. 1999. Biological wastewater treatment. New York: Marcel Dekker.
11. Grung M, Källqvist T, Sakshaug S, Skurtveit S, Thomas KV. 2008. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline. Ecotox Environ Safety 71:328-340.
12. Hai FI, Li XQ, Price WE, Nghiem LD. 2011. Removal of carbamazepine and sulfamethoxazole by MBR under anoxic and aerobic conditions. Bioresour Technol 102(22):10386-10390.
13. Henze M, Grady CPL, Jr., Gujer W, Marais GVR, Matsuo T. 1987. A general model for single-sludge wastewater treatment systems. Water Res 21:505-515.
14. Khunjar WO, Mackintosh SA, Skotnicka-Pitak J, Baik S, Aga DS, Love NG. 2011. Elucidating the relative roles of ammonia oxidizing and heterotrophic bacteria during the biotransformation of 17α-ethinylestradiol and trimethoprim. Environ Sci Technol 45(8):3605-3612.
15. Joss A, Keller E, Alder AC. 2005. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res 39(14):3139-3152.
16. Joss A, Zabczynski S, Göbel A, Hoffmann B, Löffler D, McArdell CS, Ternes TA, Thomsen A, Siegrist H. 2006. Biological degradation of pharmaceuticals in municipal wastewater treatment: Proposing a classification scheme. Water Res 40(8):1686-1696.
17. Langford K, Reid M, Thomas KV. 2011. Multi-residue screening of prioritised human pharmaceuticals, illicit drugs and bactericides in sediments and sludge. J Environ Mon 13(8):2284-2291.
18. Langford K, Thomas KV. 2011. Input of selected human pharmaceutical metabolites into the Norwegian aquatic environment. J Environ Mon 13(2):416-421.
19. Lishman L, Smyth SA, Sarafin K, Kleywegt S, Toito J, Peart T, Lee B, Servos M, Beland M, Seto P. 2006. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. Sci Total Environ 367(2-3):544-558.
20. Matsuo H, Sakamoto H, Arizono K, Shinohara R. 2011. Behavior of pharmaceuticals in waste water treatment plant in Japan. Bull Environ Contam Toxicol 87(1):31-35.
21. Miao XS, Yang JJ, Metcalfe CD. 2005. Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. Environ Sci Technol 39(19):7469-7475.
22. Nelder JA, Mead R. 1964. A simplex method for function minimization. Comput J 7:308-313.
23. Ort C, Hollender J, Schaerer M, Siegrist H. 2009. Model-based evaluation of reduction strategies for micropollutants from wastewater treatment plants in complex river networks. Environ Sci Technol 43(9):3214-3220.
24. Ort C, Lawrence MG, Rieckermann J, Joss A. 2010. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: Are your conclusions valid? a critical review. Environ Sci Technol 44(16):6024-6035.
25. Pérez S, Barceló D. 2008. First evidence for occurrence of hydroxylated human metabolites of diclofenac and aceclofenac in wastewater using QqLIT-MS and QqTOF-MS. Anal Chem 80(21):8135-8145.
26. Plósz BG, Leknes H, Thomas KV. 2010a. Impacts of competitive inhibition, parent compound formation and partitioning behaviour on antibiotic micro-pollutants removal in activated sludge. Environ Sci Technol 44(2):734-742.
27. Plósz BG, Lehnberg K, Dott W, Thomas KV. 2010b. An activated sludge modelling framework for xenobiotic organic micro-pollutants (ASM-X)-Factors influencing the biodegradation and sorption processes in WWTPs. In the proceedings of 2nd IWA/WEF Wastewater Treatment Modelling Seminar, 28-31 March, 2010, Mont-Sainte-Anne, Quebec, Canada.
28. Plósz BG, Leknes H, Liltved H, Thomas KV. 2010c. Diurnal variations in the occurrence and the fate of hormones and antibiotics in activated sludge wastewater treatment in Oslo, Norway. Sci Total Environ 408(8):1915-1924.
29. Plósz BG, Weiss M, Printemps C, Essemiani K, Meinhold J. 2007. One-dimensional modelling of the secondary clarifiersfactors affecting simulation in the clarification zone and the assessment of the thickening flow dependence. Water Res 41(15):3359-3371.
30. Radjenović J, Petrović M, Barceló D. 2009. Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. Water Res 43(3):831-841.
31. Roeleveld PJ, van Loosdrecht MCM. 2002. Experience with guidelines for wastewater characterisation in The Netherlands. Water Sci Technol 45(6):77-87.
32. Spanjers H, Vanrolleghem PA, Nguyen K, Vanhooren H, Patry GG. 1998. Towards a simulation-benchmark for evaluating respirometry-based control strategies. Water Sci Technol 37(12):219-226.
33. Strenn B, Clara M, Gans O, Kreuzinger N. 2004. Carbamazepine, diclofenac, ibuprofen and bezafibrate-Investigations on the behaviour of selected pharmaceuticals during wastewater treatment. Water Sci Technol 50(5):269-276.
34. Suarez S, Lema JM, Omil F. 2010. Removal of Pharmaceutical and Personal Care Products (PPCPs) under nitrifying and denitrifying conditions. Water Res 44(10):3214-3224.
35. Ternes TA, Joss A. 2006. Human pharmaceuticals, hormones and fragrances-The challenge of micropollutants in urban water management. London: IWA Publishing.
36. Sui Q, Huang J, Deng S, Chen W, Yu G. 2011. Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in different biological wastewater treatment processes. Environ Sci Technol 45(8):3341-3348.
37. Ternes TA, Herrmann N, Bonerz M, Knacker T, Siegrist H, Joss A. 2004. A rapid method to measure the solid-water distribution coefficient (K-d) for pharmaceuticals and musk fragrances in sewage sludge. Water Res 38(19):4075-4084.
38. Tran NH, Urase T, Kusakabe O. 2009. The characteristics of enriched nitrifier culture in the degradation of selected pharmaceutically active compounds. J Hazard Mater 171(1-3):1051-1057.
39. Urase T, Kikuta T. 2005. Separate estimation of adsorption and degradation of pharmaceutical substances and estrogens in the activated sludge process. Water Res 39(7):1289-1300.
40. Vanhooren H, Meirlaen J, Amerlinck Y, Claeys F, Vangheluwe H, Vanrolleghem PA. 2003. WEST: Modelling biological wastewater treatment. J Hydroinform 5(1):27-50.
41. Wang X, Grady CPL, Jr. 1995. Effects of biosorption and dissolution on the biodegradation of di-n-butyl phthalate. Water Environ Res 67:863-871.
42. Wick A, Fink G, Joss A, Siegrist H, Ternes TA. 2008. Fate of beta blockers and psycho-active drugs in conventional wastewater treatment. Water Res 43(4):1060-1074.
43. Zhang YJ, Geissen SU, Gal C. 2008. Carbamazepine and diclofenac: Removal in wastewater treatment plants and occurrence in water bodies. Chemosphere 73(8):1151-1161.
44. Zhang YJ, Geissen SU. 2010. Prediction of carbamazepine in sewage treatment plant effluents and its implications for control strategies of pharmaceutical aquatic contamination. Chemosphere 80(11):1345-1352.